Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.

Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, Clements PJ.

Arthritis Rheum. 2009 Dec;60(12):3821-30. doi: 10.1002/art.24986.

2.

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.

Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE.

Arthritis Rheum. 2001 Jun;44(6):1351-8.

3.
4.

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, Seney S, Summers K.

Arthritis Rheum. 2011 Nov;63(11):3547-51. doi: 10.1002/art.30549.

5.

Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.

Gordon JK, Martyanov V, Magro C, Wildman HF, Wood TA, Huang WT, Crow MK, Whitfield ML, Spiera RF.

Arthritis Res Ther. 2015 Aug 18;17:213. doi: 10.1186/s13075-015-0721-3.

6.

Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.

Quillinan NP, McIntosh D, Vernes J, Haq S, Denton CP.

Ann Rheum Dis. 2014 Jan;73(1):56-61. doi: 10.1136/annrheumdis-2013-203674. Epub 2013 Sep 25.

7.

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.

Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2007 Jan;56(1):323-33.

8.

Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.

Chakravarty EF, Martyanov V, Fiorentino D, Wood TA, Haddon DJ, Jarrell JA, Utz PJ, Genovese MC, Whitfield ML, Chung L.

Arthritis Res Ther. 2015 Jun 13;17:159. doi: 10.1186/s13075-015-0669-3.

9.

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

Merkel PA, Silliman NP, Clements PJ, Denton CP, Furst DE, Mayes MD, Pope JE, Polisson RP, Streisand JB, Seibold JR; Scleroderma Clinical Trials Consortium.

Arthritis Rheum. 2012 Oct;64(10):3420-9. doi: 10.1002/art.34427.

10.

Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.

Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Taïeb A.

Br J Dermatol. 2012 Nov;167(5):1138-44. doi: 10.1111/j.1365-2133.2012.11186.x. Epub 2012 Oct 5.

PMID:
23039171
11.

Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis.

Ostojic P, Damjanov N.

Rheumatol Int. 2011 Aug;31(8):1051-4. doi: 10.1007/s00296-010-1398-1. Epub 2010 Mar 23.

PMID:
20309694
12.

A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.

Genovese MC, Chakravarty EF, Boyle DL, Tutuncu Z, Thorburn CM, Halilhodzic M, Kroll S, Baughman J, Stewart S, Kavanaugh A.

J Rheumatol. 2005 Dec;32(12):2345-50.

PMID:
16331761
13.

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK.

Ann Rheum Dis. 2011 Jun;70(6):1003-9. doi: 10.1136/ard.2010.143974. Epub 2011 Mar 11.

14.

Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.

Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N, Denton CP.

J Rheumatol. 2010 Jan;37(1):116-24. doi: 10.3899/jrheum.090668. Epub 2009 Dec 1.

PMID:
19955050
15.

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.

Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; EUSTAR Rituximab study group.

Ann Rheum Dis. 2015 Jun;74(6):1188-94. doi: 10.1136/annrheumdis-2013-204522. Epub 2014 Jan 17.

PMID:
24442885
16.

The correlation between durometer score and modified Rodnan skin score in systemic sclerosis.

Moon KW, Song R, Kim JH, Lee EY, Lee EB, Song YW.

Rheumatol Int. 2012 Aug;32(8):2465-70. doi: 10.1007/s00296-011-1993-9. Epub 2011 Jul 19.

PMID:
21769489
17.

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2017 Jul;76(7):1207-1218. doi: 10.1136/annrheumdis-2016-210503. Epub 2017 Feb 10.

18.

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Khanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, Mayes MD, White B, Wigley FF, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen VD, Martin RW, Collier D, Weinstein A, Lally EV, Varga J, Weiner SR, Andrews B, Abeles M, Clements PJ.

Ann Rheum Dis. 2006 Oct;65(10):1325-9. Epub 2006 Mar 15.

19.

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.

Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW.

Arthritis Rheum. 2009 Feb;60(2):578-83. doi: 10.1002/art.24249.

20.

RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.

Distler O, Pope J, Denton C, Allanore Y, Matucci-Cerinic M, de Oliveira Pena J, Khanna D.

Respir Med. 2017 Jan;122 Suppl 1:S14-S17. doi: 10.1016/j.rmed.2016.09.011. Epub 2016 Sep 28.

PMID:
27746061

Supplemental Content

Support Center